• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    GE HealthCare announces U.S. FDA 510(k) clearance and CE Mark for Allia Moveo and marks first global installation, advancing precision care in the interventional suite

    2/2/26 8:00:00 AM ET
    $GEHC
    Medical Electronics
    Health Care
    Get the next $GEHC alert in real time by email
    • First worldwide Allia Moveo installation at Hôpital Marie-Lannelongue in France highlights progress in redefining interventional care delivery
    • Allia Moveo combines mobility, versatility and AI-powered tools to help clinicians navigate complex minimally invasive procedures with efficiency and accuracy

    GE HealthCare (NASDAQ:GEHC) today announced that Allia™ Moveo has received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Marking, bringing next-level mobility and precision to the interventional suite. The latest Allia platform, one of the company's bold innovations first unveiled at the Radiological Society of North America's (RSNA) 2025 Annual Meeting, assists clinicians in a wide range of cardiovascular, vascular, non-vascular, interventional and surgical procedures. Allia Moveo delivers enhanced workflow through a compact, cable-free C-arm system with an intuitive user interface, and AI-powered guidance tools to help clinicians work efficiently and adapt to the spatial constraints of traditional interventional suites.

    The Hôpital Marie-Lannelongue in France—a center of excellence in thoracic, vascular and heart surgery, and national reference for complex aortic pathologies—was the first medical center in the world to complete the installation of Allia Moveo. The platform is intended to enable flexible cone-beam computed tomography and support this leading hospital in treating vascular and cardiology diseases. The ergonomic, maneuverable system is tailored to accommodate more patients regardless of body size or weight, with a wide-bore design and effortless table panning to help care teams maintain comfort and access throughout procedures.

    "My initial experience with Allia Moveo has been incredible, it's a real game changer. With Allia Moveo, we had this opportunity to position the system very quickly in any working position that will adapt the best to us," said Stephan Haulon, M.D., Ph.D., Vascular Surgeon, Head of Aortic Center and Vascular Surgery, Hôpital Marie-Lannelongue (Le Plessis-Robinson), part of the Fondation Hôpital Saint-Joseph, Paris, France*. "One of the major milestones of this new system is having access to the reconstruction of the cone beam CT with CleaRecon DL, which is AI driven and gives you much better image quality."

    As interventional procedures grow more demanding, clinicians need imaging solutions that deliver clear insights and optimize workflows. During minimally invasive interventions involving multiple users, the ability to increase procedural confidence can depend on advanced imaging systems that can be positioned easily and quickly, capture high quality images and integrate with other technology - all while operating at a volume quieter than a normal conversation. Allia Moveo was created with clinicians to address these challenges by delivering an easy-to-use, high-performance system, built to enhance fluidity when space is at a premium.

    "With Allia Moveo, we're elevating the clinician experience, removing complexity, accelerating workflow, and enabling greater control during procedures," said Arnaud Marie, General Manager, Interventional Solutions at GE HealthCare. "We are excited to collaborate with leading experts at Hôpital Marie-Lannelongue on the first installation of this system, which is a defining step forward for care in the interventional suite, and a testament to our shared commitment to advancing meaningful innovation with the goal of supporting better outcomes for care teams and the patients they treat."

    Allia Moveo is equipped with advanced 3D imaging solutions that help clinicians visualize anatomy with confidence and make informed decisions, including:

    • CleaRecon DLi, AI-driven technology that removes streak artifacts caused by the pulsatile nature of blood flow in the arteries, delivering clearer, reliable images.
    • Motion Freeze, a tool that helps offset involuntary respiratory motion artifact to improve image clarity.
    • Metallic Artifact Reduction, designed to reveal anatomic details obscured by metal artifacts.
    • Augmented guidance solutions including ASSIST advanced clinical applications portfolio—offering augmented guidance for complex procedures—along with compatibility with other GE HealthCare and third-party systems.

    Following the first global installation of Allia Moveo at Hôpital Marie-Lannelongue, Houston's Baylor St. Luke's Medical Center, a member of CommonSpirit, marked the first installation in the United States.

    "We are honored to be the first hospital in the United States to install Allia Moveo, and proud to help advance the next generation of interventional care," said Brad Lembke, MD, President of Baylor St. Luke's Medical Center**. "This innovative platform enhances how our clinicians navigate complex minimally invasive procedures by improving mobility, image clarity, and workflow efficiency. It strengthens our ability to deliver precise, patient-centered care while supporting our teams with technology designed for the evolving demands of modern interventional medicine."

    This product may not be available in all regions, contact your GE HealthCare sales representative for more information. To learn more about Allia Moveo, visit https://www.gehealthcare.com/products/image-guiding-solutions/allia-moveo.

    *Dr. Stephan Haulon is a paid consultant for GEHC. The statements by Dr. Stephan Haulon described here are based on their own opinions and on results that were achieved in the customer's unique setting. Since there is no "typical" hospital and many variables exist, i.e. hospital size, case mix, etc. there can be no guarantee that other customers will achieve the same results.

    **The statements by Dr. Brad Lembke, described here are based on their own opinions and on results that were achieved in the customer's unique setting. Since there is no "typical" hospital and many variables exist, i.e. hospital size, case mix, etc. there can be no guarantee that other customers will achieve the same results.

    About GE HealthCare Technologies Inc.

    GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits.

    GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™.

    Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.

    i CleaRecon DL, designed to be used with Allia systems, is an option in 3DXR designed to be used with Allia systems and requires AW workstation with Volume Viewer. May not be available in all countries.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260130422339/en/

    GE HealthCare Media Contact:

    Eric Tatro

    GE HealthCare

    +1 312 459 6140

    [email protected]

    Get the next $GEHC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GEHC

    DatePrice TargetRatingAnalyst
    1/15/2026$77.00Neutral → Sell
    UBS
    10/13/2025$86.00Equal Weight
    Barclays
    10/7/2025$83.00Buy → Neutral
    Citigroup
    5/5/2025$73.00Sell → Neutral
    UBS
    3/11/2025$85.00 → $100.00Neutral → Buy
    Goldman
    1/8/2025$95.00 → $103.00Hold → Buy
    Jefferies
    9/26/2024$84.00 → $74.00Neutral → Sell
    UBS
    9/18/2024$100.00Neutral → Buy
    BTIG Research
    More analyst ratings

    $GEHC
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by GE HealthCare Technologies Inc.

    SCHEDULE 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

    3/26/26 6:37:20 PM ET
    $GEHC
    Medical Electronics
    Health Care

    SEC Form DEFA14A filed by GE HealthCare Technologies Inc.

    DEFA14A - GE HealthCare Technologies Inc. (0001932393) (Filer)

    3/19/26 7:03:57 AM ET
    $GEHC
    Medical Electronics
    Health Care

    SEC Form DEF 14A filed by GE HealthCare Technologies Inc.

    DEF 14A - GE HealthCare Technologies Inc. (0001932393) (Filer)

    3/19/26 7:02:54 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Jimenez Frank R bought $100,624 worth of shares (1,315 units at $76.52), increasing direct ownership by 2% to 75,796 units (SEC Form 4)

    4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    5/2/24 6:00:38 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GE HealthCare Recommends Shareholders Reject "Mini-Tender" Offer by Potemkin Limited

    GE HealthCare Technologies Inc. (NASDAQ:GEHC) (the "Company" or "GE HealthCare") announced today that it received notice on March 30, 2026, of an unsolicited "mini-tender" offer by Potemkin Limited to purchase up to 100,000 shares of GE HealthCare common stock at a price of $45.80 per share in cash. Potemkin Limited's offer price of $45.80 per share is approximately 34.80 percent lower than the $70.25 closing per share price of GE HealthCare's common stock on March 18, 2026, the last trading day before the mini-tender offer appears to have commenced. GE HealthCare does not endorse Potemkin Limited's unsolicited mini-tender offer and recommends that stockholders do not tender their shares

    3/31/26 4:10:00 PM ET
    $GEHC
    Medical Electronics
    Health Care

    How Decentralized AI is Unlocking Value in Cardiac Diagnostics

    ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.VANCOUVER,BC, March 27, 2026 /CNW/ -- USANewsGroup.com News Commentary – Heart disease is a quiet crisis that is draining healthcare resources worldwide, currently costing the European Union over €282 billion annually while tragically claiming 1.7 million lives a year[1]. This immense structural pressure is acting as a catalyst for smart money, with institutional capital rapidly accumulating positions in scalable, AI-enabled diagnostic platforms. In fact, peer-reviewed data now confirms that AI-driven healthcare startups command the largest share of venture funding in the entire biopharmaceutical sector[2]. At the center of this pivotal transit

    3/27/26 9:30:00 AM ET
    $BEAT
    $GEHC
    $HTFL
    Medical/Dental Instruments
    Health Care
    Medical Electronics
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    GE HealthCare announces lead industrial role in largest EU-funded IHI consortium to advance cardio-oncology care across Europe

    COMPASS is one of the largest public‑private partnerships under the European Union's (EU) Innovative Health Initiative (IHI). The consortium aims to advance early detection and prediction of cardiotoxicity in cancer patients and cancer survivors. The initiative will leverage AI, advanced imaging, biomarkers, and integrated care pathways. GE HealthCare (NASDAQ:GEHC) today announced its leading industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of cardiovascular risks in cancer patients across Europe. COMPASS combines clinical excellence with novel healthcare technology, and with a t

    3/26/26 8:30:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GE HealthCare downgraded by UBS with a new price target

    UBS downgraded GE HealthCare from Neutral to Sell and set a new price target of $77.00

    1/15/26 8:32:16 AM ET
    $GEHC
    Medical Electronics
    Health Care

    Barclays initiated coverage on GE HealthCare with a new price target

    Barclays initiated coverage of GE HealthCare with a rating of Equal Weight and set a new price target of $86.00

    10/13/25 8:53:16 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare downgraded by Citigroup with a new price target

    Citigroup downgraded GE HealthCare from Buy to Neutral and set a new price target of $83.00

    10/7/25 8:57:17 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lobo Kevin was granted 777 shares (SEC Form 4)

    4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    3/17/26 4:08:18 PM ET
    $GEHC
    Medical Electronics
    Health Care

    SEC Form 3 filed by new insider Lobo Kevin

    3 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    3/17/26 4:06:05 PM ET
    $GEHC
    Medical Electronics
    Health Care

    CEO, Patient Care Solutions Bankes Jeannette was granted 6,861 shares, increasing direct ownership by 19% to 43,892 units (SEC Form 4)

    4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    3/4/26 4:27:18 PM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Leadership Updates

    Live Leadership Updates

    View All

    GE HealthCare appoints medtech leader Kevin Lobo to Board of Directors

    GE HealthCare (NASDAQ:GEHC) announced today the appointment of Kevin A. Lobo, Chair and Chief Executive Officer of Stryker Corporation (NYSE:SYK), to its Board of Directors effective March 13. Mr. Lobo brings more than 25 years of medical technology, operational, and financial leadership experience. His clinical expertise and track record of driving innovation and scaling global businesses make him well qualified to contribute to GE HealthCare's strategic priorities. "Kevin is a seasoned healthcare executive with a deep understanding of the medical technology landscape. His knowledge and insight will further strengthen our Board as we continue to build a more personalized, connected and s

    3/17/26 9:00:00 AM ET
    $GEHC
    $SYK
    Medical Electronics
    Health Care
    Medical/Dental Instruments

    PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer

    BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025. Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across glob

    6/2/25 8:00:00 AM ET
    $GEHC
    $LNTH
    Medical Electronics
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    GE HealthCare names Jeannette Bankes president and CEO, Patient Care Solutions

    GE HealthCare (NASDAQ:GEHC), a leading global healthcare solutions provider, announced the appointment of Jeannette Bankes as president and CEO, Patient Care Solutions, effective May 1, 2025. Peter Arduini, president and CEO, GE HealthCare, said, "Jeannette is a proven leader who has diverse and deep experience at publicly traded companies in the healthcare industry. We proudly welcome her to the company and are confident that she has the expertise to move Patient Care Solutions forward and deliver on our precision care strategy." Bankes brings with her three decades of global experience including product management, marketing, sales, regulatory, medical affairs, and operations and manufa

    4/9/25 9:00:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Financials

    Live finance-specific insights

    View All

    GE HealthCare completes Intelerad acquisition – accelerating shift to cloud-first enterprise solutions to deliver precision care

    Expands GE HealthCare's enterprise imaging footprint by delivering comprehensive, end‑to‑end solutions across ambulatory, teleradiology, and hospital care settings Advances GE HealthCare's D3 strategy by accelerating the development of disease‑focused smart devices and solutions enabled by digital (cloud and software) and artificial intelligence (AI) capabilities Enhances a fully connected, cloud‑first imaging ecosystem with an expanded GE HealthCare portfolio of AI, digital tools, and SaaS offerings designed to improve clinical operations Tuck‑in acquisition expected to strengthen the Imaging portfolio, increase recurring revenue mix, and support sustainable top‑line growth and p

    3/18/26 4:00:00 PM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare announces cash dividend for first quarter of 2026

    The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the first quarter of 2026 payable on May 15, 2026, to all shareholders of record as of April 3, 2026. About GE HealthCare Technologies Inc. GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world's most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Imaging, Advanced Visualization Solutions, Patie

    2/12/26 6:11:00 PM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare reports fourth quarter and full year 2025 financial results

    Company exceeds topline and earnings per share expectations; demonstrates operational resilience Fourth quarter 2025 highlights(1) Revenue growth of 7.1%, including Organic revenue growth* of 4.8%, driven primarily by the U.S. and Europe, the Middle East and Africa (EMEA) Net income margin of 10.3% and Adjusted earnings before interest and taxes (EBIT) margin* of 16.7% Diluted earnings per share (EPS) of $1.29 and Adjusted EPS* of $1.44 Cash flow from operating activities of $1.0 billion and Free cash flow* of $916 million Full year 2025 highlights(1) Revenue growth of 4.8%, including Organic revenue growth* of 3.5% Organic orders growth of 5.2% Net income margin o

    2/4/26 6:20:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by GE HealthCare Technologies Inc.

    SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

    11/12/24 12:53:28 PM ET
    $GEHC
    Medical Electronics
    Health Care

    Amendment: SEC Form SC 13G/A filed by GE HealthCare Technologies Inc.

    SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

    10/22/24 4:16:16 PM ET
    $GEHC
    Medical Electronics
    Health Care

    SEC Form SC 13G/A filed by GE HealthCare Technologies Inc. (Amendment)

    SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

    4/2/24 4:07:29 PM ET
    $GEHC
    Medical Electronics
    Health Care